Immune Monitoring during Therapy Reveals Activitory and Regulatory Immune Responses in High-Risk Neuroblastoma
Authors:
- Celina L. SzantoCSCelina L. Szanto
- Annelisa M. CornelACAnnelisa M. Cornel
- Sara M. TammingaSTSara M. Tamminga
- Eveline M. DelemarreEDEveline M. Delemarre
- Coco C. H. de KoningCKCoco C. H. de Koning
- Denise A. M. H. van Den BeemtDBDenise A. M. H. van Den Beemt
- Ester DunnebachEDEster Dunnebach
- Michelle L. TasMTMichelle L. Tas
- Miranda P. DierselhuisMDMiranda P. Dierselhuis
- Lieve G. A. M. TytgatLTLieve G. A. M. Tytgat
- Max M. van NoeselMNMax M. van Noesel
- Kathelijne C. J. M. KraalKKKathelijne C. J. M. Kraal
Open Access
Abstract
Despite intensive treatment, including consolidation immunotherapy (IT), prognosis of high-risk neuroblastoma (HR-NBL) is poor. Immune status of patients over the course of treatment, and thus immunological features potentially explaining therapy efficacy, are largely unknown. In this study, the dynamics of immune cell subsets and their function were explored in 25 HR-NBL patients at diagnosis, during induction chemotherapy, before high-dose chemotherapy, and during IT. The dynamics of immune cells varied largely between patients. IL-2- and GM-CSF-containing IT cycles resulted in significant expansion of effector cells (NK-cells in IL-2 cycles, neutrophils and monocytes in GM-CSF cycles). Nonetheless, the cytotoxic phenotype of NK-cells was majorly disturbed at the start of IT, and both IL-2 and GM-CSF IT cycles induced preferential expansion of suppressive regulatory T-cells. Interestingly, proliferative capacity of purified patient T-cells was impaired at diagnosis as well as during therapy. This study indicates the presence of both immune-enhancing as well as regulatory responses in HR-NBL patients during (immuno)therapy. Especially the double-edged effects observed in IL-2-containing IT cycles are interesting, as this potentially explains the absence of clinical benefit of IL-2 addition to IT cycles. This suggests that there is a need to combine anti-GD2 with more specific immune-enhancing strategies to improve IT outcome in HR-NBL.Keywords
Funding Information
- Villa Joep Foundation (IWOV-Actief.51391.180034)
This publication has 44 references indexed in Scilit:
- Depletion of CD25+ T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastomaBlood, 2011
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for NeuroblastomaNew England Journal of Medicine, 2010
- Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memoryBlood, 2009
- The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force ReportJournal of Clinical Oncology, 2009
- CD25+ Regulatory T Cell Inhibition Enhances Vaccine-induced Immunity to NeuroblastomaJournal of Immunotherapy, 2007
- l-arginine availability regulates T-lymphocyte cell-cycle progressionBlood, 2006
- The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine designNature Reviews Immunology, 2006
- Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A)Cancer Immunology, Immunotherapy, 1990
- Immune evaluation of 50 children with neuroblastoma at onsetMedical and Pediatric Oncology, 1982
- Abnormalities of the immune system in children with neuroblastoma related to the neoplasm and chemotherapyThe Journal of Pediatrics, 1977